Valuation: BioNTech SE

Market Cap 25.08B 29.27B 23.47B 21.45B 40.48B 2,803B 40.92B 278B 108B 1,407B 110B 108B 4,656B P/E 2026 *
-18.1x
P/E 2027 * -19.2x
Enterprise Value 13.72B 16B 12.83B 11.73B 22.14B 1,532B 22.37B 152B 59.04B 769B 60.09B 58.79B 2,546B EV / Sales 2026 *
7.59x
EV / Sales 2027 * 8.17x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-4.45%
1 week+21.71%
Current month+23.08%
1 month+24.81%
3 months+20.86%
6 months+0.55%
Current year+17.11%
1 week 91.01
Extreme 91.01
120.33
1 month 88.2
Extreme 88.2
120.33
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
377.6
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-4.45%+21.71%+6.11%-6.35% 29.28B
-4.31%-2.14%+65.79%+103.90% 72.12B
-4.19%+1.05%+46.47%+85.53% 65.85B
-1.13%-3.25%-3.25%+466.12% 27.47B
-4.71%+7.67%+47.63%+18.25% 26.7B
-1.81%+0.38%+34.14%-18.33% 20.06B
+5.36%-1.67%+270.18%+415.10% 18.22B
-2.79%+0.48%+12.09%+562.03% 16.4B
+0.41%+3.45%+42.81%+148.85% 13.4B
-0.93%-2.45%+317.82%+208.59% 12.3B
Average -1.86%+7.76%+83.98%+198.37% 30.18B
Weighted average by Cap. -2.86%+8.44%+64.47%+156.41%

Financials

2026 *2027 *
Net sales 1.81B 2.11B 1.69B 1.55B 2.92B 202B 2.95B 20B 7.78B 101B 7.92B 7.75B 335B 1.84B 2.15B 1.72B 1.58B 2.98B 206B 3.01B 20.41B 7.94B 103B 8.08B 7.9B 342B
Net income -1.35B -1.57B -1.26B -1.15B -2.18B -151B -2.2B -14.93B -5.8B -75.65B -5.91B -5.78B -250B -1.31B -1.53B -1.23B -1.12B -2.12B -147B -2.14B -14.54B -5.65B -73.67B -5.75B -5.63B -244B
Net Debt -11.37B -13.27B -10.64B -9.72B -18.35B -1,270B -18.54B -126B -48.94B -638B -49.81B -48.73B -2,110B -10.03B -11.7B -9.38B -8.58B -16.19B -1,121B -16.36B -111B -43.18B -563B -43.95B -43B -1,862B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
25/08/26 USD 111.49 -4.36% 930,436
21/08/26 USD 116.57 +5.12% 2,960,787
20/08/26 USD 110.89 -1.97% 3,534,286
19/08/26 USD 113.12 +21.96% 8,780,347
18/08/26 USD 92.75 +1.26% 921,586
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
99.85EUR
Average target price
104.04EUR
Spread / Average Target
+4.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock